Ticagrelor + clopidogrel
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Peripheral Artery Disease
Conditions
Peripheral Artery Disease, Vascular Disease, Arterial Occlusion Disease, Intermittent Claudication, Ankle Brachial Index (0.9 or Less)
Trial Timeline
Dec 1, 2014 → Feb 1, 2016
NCT ID
NCT02121288About Ticagrelor + clopidogrel
Ticagrelor + clopidogrel is a approved stage product being developed by AstraZeneca for Peripheral Artery Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02121288. Target conditions include Peripheral Artery Disease, Vascular Disease, Arterial Occlusion Disease.
What happened to similar drugs?
19 of 20 similar drugs in Peripheral Artery Disease were approved
Approved (19) Terminated (3) Active (1)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04069234 | Phase 3 | Withdrawn |
| NCT03437044 | Approved | Completed |
| NCT02617290 | Phase 3 | Completed |
| NCT02663713 | Approved | Completed |
| NCT02319941 | Phase 2 | Completed |
| NCT02457130 | Approved | UNKNOWN |
| NCT02379676 | Approved | UNKNOWN |
| NCT02121288 | Approved | Withdrawn |
| NCT02233790 | Approved | UNKNOWN |
| NCT02618733 | Pre-clinical | Completed |
| NCT02052635 | Approved | Terminated |
| NCT01826175 | Approved | Withdrawn |
| NCT01864005 | Approved | Completed |
| NCT01732822 | Phase 3 | Completed |
| NCT01706510 | Approved | Completed |
| NCT01603082 | Approved | Completed |
| NCT01523366 | Approved | Completed |
| NCT01523392 | Approved | Completed |
| NCT01118325 | Phase 2 | Completed |
| NCT00391872 | Phase 3 | Completed |
Competing Products
20 competing products in Peripheral Artery Disease